NCT07685054Not yet recruiting
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.
A Multicenter, Prospective Observational Study to Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe' in Patients With Essential Hypertension and Primary Hypercholesterolemia.
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or the combination of fimasartan, atorvastatin, and ezetimibe.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 12700 (estimated)
- First submitted
- 28 Jun 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 15 Aug 2029
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
- NCT number
- NCT07685054
What you commit to
- Study type: Observational
- Planned participants: 12700
- From 1 Aug 2026 to the primary completion date, 15 Aug 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received concomitant administration of fimasartan and atorvastatin within 4 weeks prior to baseline.
- Patients who have received investigational or study drugs from another clinical trial or research study within 12 weeks prior to baseline. However, participation in non-interventional observational studies is permitted.
Other
- Patients with any contraindication to fimasartan, atorvastatin, or ezetimibe as specified in the approved product labeling.
- Patients considered unsuitable for study participation at the discretion of the principal investigator or sub-investigator.
Who the study is looking for
- Those who are briefed about the clinical trial objectives and methods, and express their consent to participate in the trial by signing a written consent on the use of their personal information.
- Patients diagnosed with essential hypertension and primary hypercholesterolemia.
- Patients scheduled to receive either fimasartan plus atorvastatin or fimasartan plus atorvastatin plus ezetimibe.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.